We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+1.53%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.93B
AUM Growth
-$733M
Cap. Flow
-$466M
Cap. Flow %
-9.46%
Top 10 Hldgs %
45.48%
Holding
165
New
19
Increased
18
Reduced
16
Closed
21

Top Buys

Rank Stock Value
1
OTLY
Oatly Group
OTLY
+$37.3M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$32.5M
3
TRML
Tourmaline Bio
TRML
+$31.6M
4
SAGE
Sage Therapeutics
SAGE
+$24.7M
5
VERV
Verve Therapeutics
VERV
+$20.8M

Top Sells

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$98.3M
2
INTC icon
Intel
INTC
+$47M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$38.4M
4
AVGO icon
Broadcom
AVGO
+$34.8M
5
BEKE icon
KE Holdings
BEKE
+$34.2M

Sector Composition

Rank Sector Weight
1 Healthcare 74.23%
2 Consumer Discretionary 10.87%
3 Consumer Staples 0.74%
4 Industrials 0.47%
5 Materials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTLA icon
26
Intellia Therapeutics
NTLA
$1.49B
$40.5M 0.82%
250,000
– –
DNLI icon
27
Denali Therapeutics
DNLI
$3.79B
$39.2M 0.8%
500,000
– –
BHVN
28
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$38.8M 0.79%
+400,000
New +$32.5M
OTLY
29
Oatly Group
OTLY
$470M
$36.7M 0.74%
+75,000
New +$37.3M
FOLD
30
DELISTED
Amicus Therapeutics
FOLD
$36.1M 0.73%
3,750,000
– –
REPL icon
31
Replimune Group
REPL
$405M
$34.6M 0.7%
900,000
+100,000
+13% +$3.42M
KRYS icon
32
Krystal Biotech
KRYS
$10.7B
$34M 0.69%
500,000
– –
AGEN
33
Agenus
AGEN
$279M
$32.9M 0.67%
305,700
– –
KRON
34
DELISTED
Kronos Bio
KRON
$31.6M 0.64%
1,317,954
– –
TGTX icon
35
TG Therapeutics
TGTX
$8.32B
$31M 0.63%
800,000
-700,000
-47% -$27.5M
TRML
36
DELISTED
Tourmaline Bio
TRML
$30.3M 0.62%
+206,426
New +$31.6M
VERV
37
DELISTED
Verve Therapeutics
VERV
$30.1M 0.61%
+500,000
New +$20.8M
DRNA
38
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$29.9M 0.61%
800,000
– –
FCX icon
39
CALL
Freeport-McMoran
FCX
$85.6B
$27.8M 0.56%
750,000
-250,000
-25% -$9.74M
ALXO icon
40
ALX Oncology
ALXO
$264M
$27.3M 0.55%
500,000
-25,000
-5% -$1.5M
TPTX
41
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$27.3M 0.55%
350,000
+37,300
+12% +$2.76M
ITOS
42
DELISTED
iTeos Therapeutics
ITOS
$25.5M 0.52%
994,047
-100,000
-9% -$2.38M
FMTX
43
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$24.9M 0.51%
1,000,000
– –
TRIL
44
DELISTED
Trillium Therapeutics Inc.
TRIL
$24.3M 0.49%
2,500,000
– –
CAR icon
45
Avis
CAR
$5.18B
$23.4M 0.47%
300,000
-150,000
-33% -$12.4M
ATRA icon
46
Atara Biotherapeutics
ATRA
$70.4M
$23.3M 0.47%
60,000
-20,000
-25% -$7.13M
SQZ
47
DELISTED
SQZ Biotechnologies Company
SQZ
$23.2M 0.47%
1,606,309
– –
ACHL
48
DELISTED
Achilles Therapeutics
ACHL
$22.1M 0.45%
2,255,375
– –
TSHA icon
49
Taysha Gene Therapies
TSHA
$1.56B
$22.1M 0.45%
1,040,882
– –
PRAX icon
50
Praxis Precision Medicines
PRAX
$8.22B
$21.9M 0.45%
80,000
+30,000
+60% +$10.7M
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2021 Portfolio in Review

As of Q2 2021, Artal Group held 165 positions worth $4.93B, down 13% from $5.66B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Artal Group withdrew a net $466M in Q2 2021, closing 21 positions and reducing 16 holdings. Its most notable exit was BioNTech, an estimated $98.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 69% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

Against the trend, Artal Group opened a new position in Oatly Group worth $36.7M.

  • Artal Group's largest Q2 2021 buy was Oatly Group: 75,000 shares worth $36.7M.
  • Artal Group added most to Sage Therapeutics in Q2 2021, an estimated $24.7M increase.
  • Artal Group's biggest Q2 2021 reduction was TG Therapeutics, cutting an estimated $27.5M.
  • Artal Group fully exited BioNTech in Q2 2021, selling an estimated $98.3M.
  • Artal Group's ten largest holdings make up 45% of its $4.93B portfolio in Q2 2021.
  • Artal Group opened 19 new positions and closed 21 in Q2 2021.
  • Artal Group's portfolio value fell 13% quarter-over-quarter to $4.93B.

Based on Artal Group's 13F filing for Q2 2021, filed 13 Aug 2021.